Voyager Therapeutics (VYGR) Cash & Equivalents (2014 - 2026)

Voyager Therapeutics has disclosed Cash & Equivalents across 13 years of filings, most recently posting $43.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $43.3 million, down 42.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.3 million (down 42.06% YoY), and the FY2025 annual result was $65.3 million, down 8.5% from the prior year.
• Cash & Equivalents came in at $43.3 million for Q1 2026 at Voyager Therapeutics, down from $65.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $268.3 million in Q1 2023 to a low of $43.3 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $76.1 million (2024), against an average of $101.7 million.
• Across the five-year window, Cash & Equivalents soared 211.88% in 2023 and sank 68.84% in 2024, its largest moves.
• Voyager Therapeutics' Cash & Equivalents stood at $99.0 million in 2022, then plunged by 30.47% to $68.8 million in 2023, then increased by 3.73% to $71.4 million in 2024, then slipped by 8.5% to $65.3 million in 2025, then slumped by 33.67% to $43.3 million in 2026.
• The last three Cash & Equivalents figures came in at $43.3 million (Q1 2026), $65.3 million (Q4 2025), and $45.1 million (Q3 2025), per Business Quant data.